Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer
Experts discuss specific biomarkers or clinical features that would prompt earlier consideration of trastuzumab deruxtecan or other HER2-directed therapies.
EP: 1.HER2- Upper GI Cancer
EP: 2.Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy
EP: 3.Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment
EP: 4.The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer
EP: 5.Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer
EP: 6.Navigating Prognosis and Treatment Goals in Upper GI Cancer: A Patient- and Family-Centered Approach
EP: 7.Megan’s Journey With HER2+ Upper GI Cancer
EP: 8.Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer
EP: 9.ADCs in HER2+ Gastric Cancer
Now Viewing
EP: 10.Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer
EP: 11.Considerations for Combinations Beyond Progression in Upper GI Cancer
EP: 12.Exploring Next-Line Options in HER2- MSS Gastric Cancer
Video content above is prompted by the following:
- Are there specific biomarkers or clinical features that would prompt earlier consideration of trastuzumab deruxtecan or other HER2-directed therapies?
Recent Videos
Related Content
